Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.

Srikanthan A, Ethier JL, Ocana A, Seruga B, Krzyzanowska MK, Amir E.

PLoS One. 2015 Mar 27;10(3):e0122735. doi: 10.1371/journal.pone.0122735. eCollection 2015.

2.

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.

Jang S, Zheng C, Tsai HT, Fu AZ, Barac A, Atkins MB, Freedman AN, Minasian L, Potosky AL.

Cancer. 2016 Jan 1;122(1):124-30. doi: 10.1002/cncr.29728. Epub 2015 Oct 6.

3.

Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.

Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z.

Urol Oncol. 2013 Nov;31(8):1800-5. doi: 10.1016/j.urolonc.2012.04.019. Epub 2012 May 31.

PMID:
22658883
4.

Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.

Miyake H, Imai S, Harada K, Fujisawa M.

Clin Genitourin Cancer. 2016 Feb;14(1):e19-24. doi: 10.1016/j.clgc.2015.08.002. Epub 2015 Aug 15.

PMID:
26382221
5.

Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.

La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.

Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.

PMID:
19745694
6.

Tyrosine kinase inhibitor induced pancreatitis.

Sevin A, Chen A, Atkinson B.

J Oncol Pharm Pract. 2013 Sep;19(3):257-60. doi: 10.1177/1078155212457968. Epub 2012 Oct 3.

PMID:
23034406
7.

Heart failure associated with small molecule tyrosine kinase inhibitors.

Imran TF, Shah R, Ha AS, Thomas R, Joseph J.

Int J Cardiol. 2016 Mar 1;206:110-1. doi: 10.1016/j.ijcard.2016.01.059. Epub 2016 Jan 6. No abstract available.

PMID:
26785036
8.

Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.

Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ.

J Oncol Pharm Pract. 2011 Sep;17(3):197-202. doi: 10.1177/1078155210378913. Epub 2010 Aug 4.

PMID:
20685771
9.

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H.

J Clin Oncol. 2008 Nov 10;26(32):5204-12. doi: 10.1200/JCO.2007.15.6331. Epub 2008 Oct 6.

PMID:
18838713
10.

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.

Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, Vyzula R, Abrahamova J, Buchler T; Czech Renal Cancer Cooperative Group.

Ann Oncol. 2012 Dec;23(12):3137-43. doi: 10.1093/annonc/mds145. Epub 2012 Jun 13.

PMID:
22700990
11.

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.

Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF.

BJU Int. 2012 Sep;110(5):692-8. doi: 10.1111/j.1464-410X.2012.10946.x. Epub 2012 Feb 24.

12.

Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.

Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, Do Cao C, Chougnet CN, Leboulleux S, Baudin E, Schlumberger M, de la Fouchardière C.

Eur J Endocrinol. 2014 Mar 8;170(4):575-82. doi: 10.1530/EJE-13-0825. Print 2014 Apr.

PMID:
24424318
13.

Sorafenib and sunitinib for elderly patients with renal cell carcinoma.

Derbel Miled O, Dionne C, Terret C, Segura-Ferlay C, Flechon A, Neidhart EM, Negrier S, Droz JP.

J Geriatr Oncol. 2013 Jul;4(3):255-61. doi: 10.1016/j.jgo.2013.04.004. Epub 2013 May 9.

PMID:
24070463
14.

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL.

J Clin Endocrinol Metab. 2010 Jun;95(6):2588-95. doi: 10.1210/jc.2009-1923. Epub 2010 Apr 14.

PMID:
20392874
15.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.

PMID:
19558553
16.

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.

Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D.

Eur J Cancer. 2013 Mar;49(5):1027-31. doi: 10.1016/j.ejca.2012.10.009. Epub 2012 Nov 6.

PMID:
23140824
17.

The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.

Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, Lacouture ME.

J Drugs Dermatol. 2012 Nov;11(11):e61-5.

PMID:
23135095
18.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

19.

Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.

Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T.

Jpn J Clin Oncol. 2012 Aug;42(8):742-7. doi: 10.1093/jjco/hys076. Epub 2012 May 23.

PMID:
22628612
20.

Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.

Abdel-Rahman O, Fouad M.

Crit Rev Oncol Hematol. 2014 Dec;92(3):194-207. doi: 10.1016/j.critrevonc.2014.06.003. Epub 2014 Jul 1. Review.

PMID:
25028151

Supplemental Content

Support Center